Anthony Hagen
Advertisement
Articles by Anthony Hagen
The FDA will reassess 6 indications for immune checkpoint inhibitors that were granted accelerated approval but failed to prove clinical benefit in confirmatory trials.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success
2
OneOncology Partners With OpenEvidence to Give Physicians Access Within Clinical Workflows
3
High-Dose Vitamin D3 Fails to Improve PFS in Phase 3 Metastatic CRC Trial
4
Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups
5